Aarti Drugs (NSE: AARTIDRUGS) profit climbs 29% in Q2 FY26 as export-led growth drives margin gains

How did Aarti Drugs Limited perform in Q2 FY26 amid margin resilience and export-led demand?

Aarti Drugs Limited (NSE: AARTIDRUGS, BSE: 524348), a diversified Indian pharmaceutical manufacturer, posted a strong 29 percent year-on-year rise in consolidated profit after tax for the quarter ended September 30, 2025. This growth was driven by robust export volumes, improved product mix, and operational cost efficiencies. Revenue rose 9 percent year-on-year to ₹652.9 crore in Q2 FY26, while EBITDA increased 23 percent to ₹84.4 crore, with the EBITDA margin expanding by 150 basis points to 12.9 percent. Profit after tax reached ₹45.2 crore, up from ₹35 crore in the same quarter last year, with PAT margin improving from 5.8 percent to 6.9 percent.

The results, announced on November 7, 2025, highlight the company’s continued focus on backward integration, cost competitiveness, and scale utilization. Aarti Drugs Limited has been navigating a mixed operating environment, where domestic demand, particularly in the antibiotics segment, has remained muted. However, the company has managed to offset this softness through export gains and capacity additions across its integrated API and specialty chemicals operations.

What are the consolidated financial highlights for H1 FY26 and how do they compare to last year?

For the first half of fiscal 2026, Aarti Drugs Limited reported revenue of ₹1,243.7 crore, up 8 percent compared to ₹1,156.3 crore in H1 FY25. EBITDA for the period stood at ₹158.8 crore, an 18 percent increase over the same period last year. Net profit rose sharply by 45 percent to ₹99.1 crore, indicating stronger operating leverage and export mix benefits. The PAT margin for the six-month period stood at 8.0 percent, up from 5.9 percent in H1 FY25, reflecting a 210 basis point expansion.

Gross profit improved to ₹462 crore for the half year, compared to ₹402.4 crore in the previous year, primarily due to lower input cost pressure and the scaling of backward integrated raw material facilities. The EBITDA margin rose to 12.8 percent from 11.6 percent in H1 FY25. Earnings per share for the six-month period increased to ₹10.86, compared to ₹7.48 in the prior year, offering a strong indicator of shareholder value creation.

How are different business segments contributing to the overall revenue and growth?

Aarti Drugs Limited’s Active Pharmaceutical Ingredients (API) segment remains the largest contributor, generating ₹515.9 crore in revenue in Q2 FY26, up 7 percent year-on-year. The quarter also saw a sequential improvement of 13 percent, highlighting a recovery in operational throughput. The formulation segment grew 26 percent to ₹82.4 crore in Q2 FY26, with exports accounting for 68 percent of the revenue in this vertical.

Specialty chemicals revenue surged by 30 percent year-on-year to ₹37.3 crore during the quarter. This strong growth reflects the company’s progress in capturing higher-value demand in regulated markets and reducing import dependence. On the other hand, the intermediates and other segment saw a year-on-year decline of 20 percent, with revenue falling to ₹17.1 crore due to demand softness in specific end-use markets.

Over H1 FY26, formulations revenue reached ₹162.8 crore, up 20 percent year-on-year. Exports accounted for 63 percent of this segment’s sales, reflecting growing traction in global markets where the company has obtained several new certifications from regulatory authorities in the United States and European Union.

What strategic milestones were achieved by Aarti Drugs Limited during the quarter in terms of integration and capacity expansion?

The quarter marked significant progress in Aarti Drugs Limited’s backward integration efforts. The commissioning of its Sayakha amines plant in September 2025 enabled the company to fulfill nearly 40 to 50 percent of its metformin intermediate requirements through captive production. Management expects this figure to rise to 100 percent within the next two to three quarters. This move is seen as a key driver for gross margin stability and cost insulation.

Additionally, the company’s salicylic acid operations at Tarapur are stabilizing at around 300 tonnes per month, with a targeted ramp-up to 500 tonnes per month by the fourth quarter of FY26. A downstream salicylates line is under implementation, which will feed an additional 400 tonnes per month capacity. This downstream vertical is expected to boost operating margins through better overhead absorption and value-chain integration.

These backward integration projects are core to Aarti Drugs Limited’s broader strategy of reducing import dependency, improving margin resilience, and meeting export market quality standards. Capex during the quarter stood at approximately ₹45.6 crore and is largely focused on these capacity additions and integration projects.

How did the standalone business and regional market exposure evolve during Q2 FY26?

The standalone business contributed 89 percent to the consolidated revenue in Q2 FY26, with revenue rising 7 percent year-on-year to ₹578.9 crore. However, the performance within geographic markets was bifurcated. Domestic revenue declined 7 percent year-on-year, largely due to demand contraction in the antibiotics therapeutic class. Meanwhile, export revenue grew 33 percent year-on-year, contributing 42 percent to standalone revenues.

Within the API category, antibiotics accounted for 36.1 percent of total API revenue, followed by antiprotozoals at 18.8 percent, antidiabetics at 15.3 percent, anti-inflammatory therapies at 11.8 percent, and antifungals at 11.7 percent. The remaining 6.4 percent was spread across other therapeutic classes, demonstrating a relatively diversified portfolio across therapeutic needs.

This export-led mix is becoming increasingly central to Aarti Drugs Limited’s revenue stability as it transitions from domestic-focused volumes to global regulatory-compliant product manufacturing.

What is the current stock market sentiment and trading activity around Aarti Drugs Limited?

As of market close on November 7, 2025, Aarti Drugs Limited shares were trading at ₹491.50, up ₹2.60 or 0.53 percent from the previous close. The stock opened at ₹485 and touched an intraday high of ₹499.90. The 52-week high for the stock stands at ₹564.05, while the 52-week low was ₹312.00, highlighting a robust recovery from its April 2025 lows.

The stock traded on volumes of 4.13 lakh shares, generating a traded value of ₹20.18 crore. The adjusted price-to-earnings (P/E) ratio stands at 23.64, and the total market capitalization is ₹4,485.92 crore. The free float market cap is ₹1,715.71 crore, with a traded-to-deliverable percentage of 25.91 percent, suggesting moderate retail activity.

Institutional sentiment toward the stock has shown signs of stabilization, with recent domestic institutional investor interest re-emerging as the company demonstrated consistent margin gains and export growth. Foreign institutional inflows remain subdued but are expected to track upward pending further regulatory approvals in the United States and Europe for key API and formulation exports.

What is the forward-looking outlook for Aarti Drugs and its long-term investment narrative?

Management expects that over the next three financial years, from FY27 to FY29, the full benefits of its capex cycle will reflect in earnings, with the Sayakha and Tarapur expansions contributing to both top-line growth and margin stability. Certifications from EU and USFDA regulators for new product lines and large-scale facilities are expected to unlock additional revenue streams from regulated markets, further reducing dependency on volatile domestic demand.

Operational cash flows are strengthening, with the majority of capex spend already completed, shifting the company’s focus toward scaling utilization and converting investments into returns. This strategy, supported by higher-value products, integrated supply chains, and global certifications, is positioning Aarti Drugs Limited to become a more stable earnings compounder in the Indian pharmaceutical export landscape.

While risks around domestic pricing, input inflation, and global regulatory shifts remain, Aarti Drugs Limited’s integrated model and export-heavy orientation are seen by analysts as providing a cushion against sector-wide volatility.

Key takeaways: What should investors know about Aarti Drugs Limited’s Q2 FY26 performance?

• Aarti Drugs Limited reported consolidated revenue of ₹652.9 crore in Q2 FY26, marking a 9 percent year-on-year increase driven by export strength.
• Profit after tax for Aarti Drugs Limited rose 29 percent year-on-year to ₹45.2 crore, with PAT margin improving from 5.8 percent to 6.9 percent.
• For H1 FY26, Aarti Drugs Limited posted revenue of ₹1,243.7 crore and a 45 percent year-on-year jump in PAT to ₹99.1 crore, reflecting strong operating leverage.
• Export revenue for Aarti Drugs Limited surged 33 percent year-on-year in Q2 FY26, helping offset a 7 percent drop in domestic sales.
• The API segment remained the largest contributor to Aarti Drugs Limited’s topline, delivering ₹515.9 crore in Q2 revenue.
• The formulation segment of Aarti Drugs Limited grew 26 percent in Q2 FY26, with 68 percent of sales coming from international markets.
• Specialty chemicals revenue for Aarti Drugs Limited jumped 30 percent year-on-year in Q2 FY26, reflecting backward integration gains.
• Aarti Drugs Limited commissioned its Sayakha amines plant during the quarter, now fulfilling 40–50 percent of internal metformin needs, targeting 100 percent by FY26 end.
• Salicylic acid output from Aarti Drugs Limited’s Tarapur facility reached 300 tonnes/month, with 500 tonnes/month targeted by Q4 FY26.
• Aarti Drugs Limited stock closed at ₹491.50 on November 7, 2025, with a 52-week high of ₹564.05, signaling moderate investor optimism amid export-led recovery.